Fundraising FoxGallant Therapeutics
1 known investors
Find your way into Gallant Therapeutics
Sign up to see every warm intro you have to Gallant Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Gallant Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Gallant develops regenerative medicine for pets using allogeneic mesenchymal stromal cell (MSC) therapies, with a pipeline targeting conditions such as feline chronic gingivostomatitis, feline and canine osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis. Its ready-to-use, intravenously administered therapies follow the FDA approval process and are offered to veterinarians and pet families across the U.S.
Investors · 1
Frequently asked questions
- What does Gallant Therapeutics do?
- Gallant develops regenerative medicine for pets using allogeneic mesenchymal stromal cell (MSC) therapies, with a pipeline targeting conditions such as feline chronic gingivostomatitis, feline and canine osteoarthritis, feline chronic kidney disease, and canine atopic dermatitis. Its ready-to-use, intravenously administered therapies follow the FDA approval process and are offered to veterinarians and pet families across the U.S.
- Who are Gallant Therapeutics's investors?
- Gallant Therapeutics's investors include Companion Fund.